B-cell Expansion with NF-κB and T-cell Anergy (BENTA) Disease

B-cell Expansion with NF-κB and T-cell Anergy is a rare, inherited immune disorder caused by gain-of-function (GOF) mutations in the gene CARD11. CARD11 sits inside lymphocytes (B and T cells) and helps switch on the NF-κB signaling pathway after the B-cell or T-cell receptor is triggered. When CARD11 is hyperactive from birth, B cells get survival and growth signals all the time, producing polyclonal B-cell lymphocytosis (too many B cells that aren’t cancer). At the same time, T cells become anergic (sluggish to respond), so infections—especially with EBV—can be more frequent or harder to control. Typical features start in infancy or early childhood: persistently high lymphocyte counts, big spleen and lymph nodes, recurrent infections, sometimes autoimmune cytopenias, and a theoretical risk of lymphoma later in life, though most children have a relatively “benign” course with careful monitoring. PubMed+2PubMed Central+2

BENTA disease is a rare, inherited immune system disorder. The full name means B-cell Expansion with NF-κB and T-cell Anergy. In simple words, the body makes too many B cells because a cell-signaling switch called NF-κB is turned on too strongly. At the same time, T cells become “anergic,” which means they do not respond properly when they should. This mix causes large lymph nodes, a big spleen, repeated infections in early life, and weak responses to vaccines. Many people are diagnosed in infancy or early childhood. The disease follows an autosomal dominant pattern, so one changed gene copy can cause illness. rarediseases.info.nih.gov+1

Inside lymphocytes, CARD11 teams up with BCL10 and MALT1 to form the CBM complex, which flips on NF-κB—like a master “on” switch for cell survival signals. In BENTA, GOF CARD11 means this switch is stuck partially “on” even without normal triggers, so B cells keep expanding. Meanwhile, T-cell signaling becomes abnormal, making T cells less responsive (anergy). That mixed picture—too many B cells + underperforming T cells—explains the hallmark lab findings and infection patterns seen in patients. MedlinePlus+1

The root problem is usually a gain-of-function mutation in a gene called CARD11 (also known as CARMA1). This gene helps B and T cells send signals after their receptors are triggered. When CARD11 is stuck “on,” the NF-κB pathway stays active. That keeps B cells alive and dividing, and it makes T cells less responsive. This is why we see polyclonal B-cell lymphocytosis (many B cells from many different clones) plus T-cell hyporesponsiveness. PubMed Central+2Frontiers+2

Doctors monitor people with BENTA for recurrent ear, sinus, and chest infections, splenomegaly (big spleen), lymphadenopathy (big lymph nodes), poor vaccine responses, occasional autoimmunity (like low platelets or hemolytic anemia), and possible chronic EBV or molluscum contagiosum infections. Some reports discuss a possible risk of B-cell malignancy, so long-term follow-up is important. rarediseases.info.nih.gov+2Frontiers+2

---

Other names

• BENTA disease

• B-cell Expansion with NF-κB and T-cell Anergy

• CARD11 gain-of-function immunodeficiency
  These labels all refer to the same clinical picture linked to germline CARD11 gain-of-function variants. NCBI+1

---

Types

BENTA is one disease, but doctors sometimes use practical “types” to describe how it looks in real patients:

1. Classic early-onset BENTA – infants/young children with big spleen and lymph nodes, very high B-cell counts, frequent bacterial respiratory infections. rarediseases.info.nih.gov

2. BENTA with prominent viral issues – recurrent or chronic EBV or molluscum contagiosum; prolonged viral shedding; needs careful monitoring. rarediseases.info.nih.gov

3. BENTA with autoimmunity – features like immune thrombocytopenia (easy bruising/bleeding) or autoimmune hemolytic anemia (pallor, fatigue). Frontiers

4. BENTA with “B-cell–malignancy risk” flags – persistent, marked lymphoproliferation, systemic symptoms (fever, night sweats, weight loss) requiring oncologic vigilance; actual cancer is uncommon but considered. NCBI

5. Atypical/variable expressivity – same gene change in relatives but different severity; some mild, some more symptomatic. Frontiers

---

Causes

1. Germline CARD11 gain-of-function (GOF) mutation – the core cause; a single altered copy is enough. PubMed Central+1

2. Constitutive NF-κB activation – signaling stays “on,” driving B-cell survival and growth. Frontiers

3. Enhanced B-cell receptor (BCR) signaling – CARD11 sits in the BCR pathway, amplifying downstream survival signals. MedlinePlus

4. CBM complex over-activity (CARD11–BCL10–MALT1) – the scaffold that turns on NF-κB works too strongly. MedlinePlus

5. T-cell anergy programs – chronic signaling can blunt T-cell responses to stimulation. Frontiers

6. Autosomal dominant inheritance – one mutated parent can pass it to a child (50% chance each pregnancy). Wikipedia

7. De novo mutation – the change can arise new in the child even if parents are unaffected. rarediseases.info.nih.gov

8. Skewed B-cell maturation – lower class-switched/memory B cells; more transitional/naïve cells. Frontiers

9. Impaired vaccine antibody responses – poor functional humoral immunity despite high B-cell numbers. rarediseases.info.nih.gov

10. Viral co-factors – chronic EBV may worsen lymphoproliferation or symptoms. rarediseases.info.nih.gov

11. Mucocutaneous viral susceptibility – molluscum contagiosum is reported in some patients. rarediseases.info.nih.gov

12. Cytokine environment shifts – downstream of NF-κB, pro-survival cytokines can favor B-cell expansion (mechanistic inference from pathway biology). MedlinePlus

13. Reduced T-cell proliferative capacity – lab assays show weak proliferation to stimuli. NCBI

14. Poor class switching – contributes to low quality antibody responses. Frontiers

15. Somatic parallels in lymphoma – somatic CARD11 GOF occurs in DLBCL; this informs surveillance in BENTA (germline) patients. SpringerLink

16. Domain-specific effects – many BENTA GOF variants cluster in CARD11’s coiled-coil region that controls activation. SpringerLink

17. Pathway-level overlap – other NF-κB pathway genes can cause BENTA-like states in research reports, but classic BENTA is CARD11-GOF. Frontiers

18. Immune dysregulation with autoimmunity – abnormal signaling can break tolerance and trigger autoimmune issues. Frontiers

19. Hematologic activation syndromes overlap – some BENTA features can resemble HLH presentations, complicating diagnosis. PubMed

20. Genetic background and environment – individual modifiers can change severity between patients in the same family. Frontiers

---

Symptoms

1. Frequent ear infections – pain, discharge, or fever due to weak defense in the upper airways. rarediseases.info.nih.gov

2. Repeated sinus infections – nasal blockage, facial pain, and thick mucus. rarediseases.info.nih.gov

3. Chest infections/bronchitis – cough and breathing discomfort from lower-airway infections. rarediseases.info.nih.gov

4. Enlarged lymph nodes – “lumps” in the neck, armpits, or groin due to B-cell build-up. NCBI

5. Enlarged spleen – left-upper-abdominal fullness or early satiety. NCBI

6. Fatigue – from ongoing immune activity or intercurrent infections. Frontiers

7. Fevers – with or without clear infection focus. Frontiers

8. Night sweats – sometimes accompany lymphoproliferation; require medical review. NCBI

9. Unexplained weight loss – a “red flag” that prompts careful assessment. NCBI

10. Poor response to vaccines – infections happen despite vaccination because antibody quality is low. rarediseases.info.nih.gov

11. Easy bruising or nosebleeds – can signal immune thrombocytopenia in some patients. Frontiers

12. Pale skin or shortness of breath on exertion – may reflect autoimmune hemolytic anemia. Frontiers

13. Long-lasting viral infections – such as chronic EBV. rarediseases.info.nih.gov

14. Skin bumps from molluscum contagiosum – pearly, umbilicated papules on skin. rarediseases.info.nih.gov

15. Recurrent mouth ulcers or sore throat – due to mucosal immune weakness. Frontiers

---

Diagnostic tests

A) Physical examination (bedside assessment)

1. General inspection – look for pallor, fever, weight loss, and fatigue that suggest chronic illness or autoimmunity. Frontiers

2. Lymph node survey – check neck, axillae, and groin for size, tenderness, and texture; BENTA usually shows generalized, non-tender enlargement. NCBI

3. Abdominal exam for spleen and liver – feel and percuss for splenomegaly and hepatomegaly; document size to track change. NCBI

4. ENT and chest exam – look for signs of otitis, sinusitis, and lower-respiratory infection, which are common early clues. rarediseases.info.nih.gov

B) Manual/bedside tests (simple clinician-performed maneuvers)

5. Focused lymph-node palpation mapping – charting node stations over time to monitor lymphoproliferation. NCBI

6. Spleen percussion and scratch test – quick bedside ways to screen for splenic enlargement when imaging is not immediately available. NCBI

7. Tonsil inspection – enlarged tonsils may mirror generalized lymphoid expansion. NCBI

8. Growth and nutrition checks – children may show subtle growth impacts from frequent infections. rarediseases.info.nih.gov

C) Laboratory and pathological tests

9. Complete blood count (CBC) with differential – shows lymphocytosis driven by polyclonal B cells; may flag anemia or thrombocytopenia if autoimmunity occurs. NCBI

10. Peripheral smear review – confirms lymphocytosis morphology and screens for atypia that would need hematology input. NCBI

11. Flow cytometry (immunophenotyping) – key test: marked increase in naïve/transitional B cells, reduced class-switched memory B cells, and normal/low T-cell activation markers. Frontiers

12. Immunoglobulin levels (IgG, IgA, IgM) – patterns vary; impaired specific antibody responses are more informative than totals. rarediseases.info.nih.gov

13. Specific antibody titers to vaccines (e.g., tetanus, pneumococcus) – often low despite vaccination, supporting functional B-cell impairment. rarediseases.info.nih.gov

14. T-cell proliferation assays (e.g., response to mitogens/antigens) – show T-cell anergy or hyporesponsiveness. NCBI

15. Viral studies – EBV DNA load, serologies, and tests for molluscum or other chronic viruses if suspected. rarediseases.info.nih.gov

16. Genetic testing for CARD11 – confirms heterozygous GOF variant; typically clusters in the coiled-coil region. Testing is available via clinical labs or registries. NCBI+1

D) Electrodiagnostic tests

17. Electrodiagnostic studies (EMG/NCS/EEG) – usually not needed for BENTA itself because it is an immune, not neuromuscular or brain electrical disorder. They may be done only if another problem is suspected. This category is included here to be complete and to note their limited role. (Clinical clarification based on disease biology.) Frontiers

E) Imaging tests

18. Abdominal ultrasound – simple way to confirm and measure spleen and liver size without radiation; useful for follow-up. NCBI

19. Chest X-ray – checks for pneumonias in children with recurrent cough/fever; may also show enlarged mediastinal nodes. rarediseases.info.nih.gov

20. CT or MRI (selected cases) – used if there are red flags (e.g., very rapid node growth, systemic symptoms) to exclude lymphoma or other complications. NCBI

Non-pharmacological treatments (therapies & other care)

1. Specialist-led monitoring program
   Regular visits with pediatric immunology track blood counts, spleen size, infections, and EBV levels. Early pattern recognition allows timely antibiotics/antivirals and prevents complications. Mechanism: surveillance & early intervention reduce risk from immune dysregulation. PubMed Central

2. Vaccination optimization (inactivated vaccines)
   Updating routine non-live vaccines can reduce preventable infections; live vaccines are individualized. Mechanism: boosting humoral protection where B-cell function allows; coordinated with Ig therapy if used. Immune Deficiency Foundation

3. Infection-prevention lifestyle (hand hygiene, masks during outbreaks)
   Simple barriers cut respiratory and GI virus transmission, which is important when T-cell responses are blunted. Immune Deficiency Foundation

4. Prompt fever pathways
   Families get a “fever plan” (early clinic call, cultures, rapid antivirals/antibiotics when indicated). Mechanism: faster source control lowers complications. PubMed Central

5. EBV monitoring and counseling
   Periodic EBV PCR in blood helps catch rising viral loads early, allowing pre-emptive measures. Mechanism: EBV drives B-cell activation; keeping tabs reduces risk of severe disease. PubMed Central

6. Nutrition optimization
   Adequate calories, micronutrients, and protein support immune barriers and recovery after infections. Mechanism: corrects modifiable immune stressors. Immune Deficiency Foundation

7. Dental/ENT care plan
   Aggressive management of sinusitis/otitis/dental infections prevents chronic inflammation and bacteremia. Mechanism: remove recurring pathogen reservoirs. Immune Deficiency Foundation

8. Household infection control (vaccinated contacts)
   Cocooning reduces exposure; family members keep influenza/COVID vaccines current. Mechanism: herd protection in the home. Immune Deficiency Foundation

9. School and travel letters
   Care plans for school nurses; travel prep with destination-specific advice and standby meds. Mechanism: faster access to care, fewer delays. Immune Deficiency Foundation

10. Physical activity within tolerance
    Regular, moderate activity supports lung function and general health, tailored to splenomegaly and fatigue. Mechanism: conditioning without immunosuppressive risk. Immune Deficiency Foundation

11. Sun-safe and skin-care practices
    Lower risk from skin infections and treatment-related photosensitivity (e.g., with some antivirals/antibiotics). Mechanism: barrier integrity. FDA Access Data

12. Psychosocial support & education
    Coaching reduces anxiety, improves adherence, and empowers early symptom reporting. Mechanism: self-management improves outcomes in chronic immunologic disease. Immune Deficiency Foundation

13. All-hazard emergency card
    Wallet card summarizing diagnosis, baseline labs, and contact info aids urgent teams. Mechanism: efficient, safer acute care. Immune Deficiency Foundation

14. Antimicrobial stewardship plan
    Personalized thresholds for starting/ending antibiotics/antivirals balance infection control and resistance risks. Mechanism: right drug, right time. PubMed Central

15. Allergy/immunology-led school vaccination exemptions when appropriate
    For specific live vaccines only when risk outweighs benefit. Mechanism: risk avoidance in T-cell anergy. Immune Deficiency Foundation

16. Household food safety
    Avoid unpasteurized products/undercooked meats to cut foodborne infections. Mechanism: source control. Immune Deficiency Foundation

17. Spleen-safety counseling
    Avoid contact sports if spleen is enlarged; know rupture warning signs. Mechanism: prevent traumatic complications. PubMed Central

18. Structured follow-up for autoimmunity
    Early work-ups for cytopenias or autoimmune signs enable prompt, targeted therapy. Mechanism: limit tissue damage. PubMed Central

19. Care coordination
    Shared plans across pediatrics, hematology, infectious disease, and immunology reduce fragmentation. Mechanism: fewer gaps in care. PubMed Central

20. Genetic counseling for families
    BENTA is typically autosomal dominant; counseling helps with family testing and future planning. Mechanism: informed decisions, early detection. Wikipedia

---

Drug treatments

Important: There’s no single FDA-approved drug specifically for BENTA. Clinicians use medications off-label to control infections, autoimmunity, inflammation, or lymphoproliferation. Below, each entry explains the common rationale in BENTA-like situations, and cites the official FDA label (for its on-label indications/safety) so readers can verify dosing and warnings. Actual regimens must be individualized by specialists.

1. Sirolimus (Rapamune®)
   Why considered: mTOR inhibition may reduce lymphoproliferation and hyperactivation; case reports describe benefit in some BENTA patients. Label facts: oral immunosuppressant for renal transplant; boxed warnings for infection/malignancy risk and transplant-specific cautions; typical dosing is not for BENTA and must be expert-tailored. Common adverse effects: mouth ulcers, lipid changes, edema, cytopenias. PubMed Central+1

2. Rituximab (Rituxan®)
   Why considered: anti-CD20 monoclonal antibody depletes B cells; used off-label for autoimmune cytopenias or EBV-driven complications. Label facts: indicated for NHL/CLL, GPA/MPA, PV, etc.; warnings include infusion reactions and PML. FDA Access Data+1

3. Intravenous immunoglobulin (IVIG; e.g., Gamunex-C®)
   Why considered: supports humoral immunity when antibody function is inadequate; helpful for recurrent sinopulmonary infections or autoimmune modulation. Label facts: IVIG has product-specific labels; class warnings include thrombosis and renal dysfunction. U.S. Food and Drug Administration+1

4. Trimethoprim-Sulfamethoxazole (Bactrim®)
   Why considered: antibacterial prophylaxis for recurrent bacterial infections and sometimes for Pneumocystis jirovecii prophylaxis in immunodeficiency contexts. Label facts: broad FDA label as antibacterial; significant drug-interaction section and hypersensitivity risks. FDA Access Data+1

5. Valganciclovir (Valcyte®)
   Why considered: for significant CMV; EBV issues dominate BENTA, but CMV can occur in immunocompromised states. Label facts: antiviral prodrug of ganciclovir; hematologic toxicity and teratogenicity warnings; handling precautions. FDA Access Data+1

6. Acyclovir / Valacyclovir
   Why considered: prophylaxis/treatment of HSV/VZV reactivations in susceptible patients. Label facts: FDA-labeled for HSV/VZV; key renal dosing and neurotoxicity cautions (labels not shown here due to space; use official FDA label for the chosen product). U.S. Food and Drug Administration

7. Azithromycin
   Why considered: treatment of community respiratory infections; sometimes used in prophylaxis strategies in PID. Label facts: macrolide antibacterial with QT-prolongation risk; refer to FDA Zithromax® label. U.S. Food and Drug Administration

8. Amoxicillin-Clavulanate
   Why considered: first-line for recurrent otitis/sinusitis in many children. Label facts: FDA-approved β-lactam/β-lactamase inhibitor; GI upset and allergy are common cautions (see Augmentin® label). U.S. Food and Drug Administration

9. Prednisone/Prednisolone (systemic corticosteroids)
   Why considered: short courses for autoimmune cytopenias or inflammatory flares; taper carefully. Label facts: class warnings include infection risk, hyperglycemia, hypertension, bone effects; consult the specific FDA steroid label used. U.S. Food and Drug Administration

10. Mycophenolate mofetil (CellCept®)
    Why considered: steroid-sparing agent for autoimmune cytopenias in some PIDs. Label facts: boxed warnings (embryo-fetal toxicity, infections, malignancy); GI and cytopenias common. U.S. Food and Drug Administration

11. Abatacept (Orencia®)
    Why considered: costimulation blocker; theoretically may help T-cell anergy/autoimmunity in selected PID contexts; evidence in BENTA is limited. Label facts: infusion reactions, infection risk; check FDA label for dosing/screening. U.S. Food and Drug Administration

12. Ibrutinib (Imbruvica®) or other BTK inhibitors (investigational/off-label)
    Why considered: modulate BCR signaling; however, CARD11 GOF lies downstream of BTK, so clinical benefit may be limited—use only in trials/experts’ hands. Label facts: FDA-approved for B-cell malignancies; bleeding, atrial fibrillation, infections noted. Frontiers

13. Rituximab + antivirals (for EBV-driven lymphoproliferation)
    Combined approach sometimes used to reduce B-cell targets while controlling viral replication. Label cautions as above. PubMed Central

14. Broad-spectrum antibiotics (culture-guided)
    For acute bacterial infections with low threshold for treatment; choose agents per local guidelines and cultures to avoid resistance. FDA labels vary by product. U.S. Food and Drug Administration

15. Antifungals (e.g., fluconazole) when indicated
    For candidiasis or prophylaxis in selected scenarios; attention to drug interactions and QT prolongation. Use FDA fluconazole label. U.S. Food and Drug Administration

16. Growth-factor support (G-CSF) if secondary neutropenia occurs
    Not routine, but considered for severe, recurrent infections with neutropenia. FDA filgrastim labels detail dosing and splenic risks. U.S. Food and Drug Administration

17. Pneumocystis prophylaxis alternatives (e.g., atovaquone) when sulfa-allergic
    Used if PJP risk judged high. FDA labels outline dosing and cautions. U.S. Food and Drug Administration

18. Oseltamivir during influenza
    Early antiviral lowers complications. FDA Tamiflu® label provides pediatric dosing and timing windows. U.S. Food and Drug Administration

19. RSV monoclonal prevention (seasonal, eligibility-based)
    Products/eligibility evolve; labels outline infants/young-child criteria. Discuss yearly with specialist. U.S. Food and Drug Administration

20. Hematology-guided therapy for autoimmune cytopenias
    Can include steroid-sparing agents or rituximab as above; individualized to minimize cumulative immunosuppression. FDA Access Data

---

Dietary molecular supplements

Evidence in BENTA is not specific; these support general immune health when approved by the care team. Avoid interactions with prescribed drugs.

1. Vitamin D3 — helps barrier and innate/adaptive immune function; maintain sufficiency per pediatric guidelines; excessive dosing risks hypercalcemia. (Discuss with clinician.) Immune Deficiency Foundation

2. Zinc — supports antiviral defenses and epithelial repair; long-term high doses can cause copper deficiency. Immune Deficiency Foundation

3. Omega-3 fatty acids — anti-inflammatory lipid mediators; can modestly lower triglycerides (relevant if sirolimus raises lipids). Watch bleeding risk. FDA Access Data

4. Vitamin C — supports neutrophil function and collagen; high doses may cause GI upset/kidney stones. Immune Deficiency Foundation

5. Probiotics (strain-specific) — may reduce antibiotic-associated diarrhea; avoid in severely immunocompromised hosts. Immune Deficiency Foundation

6. Protein-adequate diet — amino acids are substrates for antibodies/immune mediators; malnutrition worsens infection risk. Immune Deficiency Foundation

7. Folate & B12 — support hematopoiesis; deficiencies worsen cytopenias. Immune Deficiency Foundation

8. Iron (only if deficient) — corrects iron-deficiency anemia; excess iron can fuel infections—check ferritin and discuss first. Immune Deficiency Foundation

9. Selenium — cofactor in antioxidant enzymes; deficiency impairs antiviral defenses; excess is toxic. Immune Deficiency Foundation

10. Electrolyte rehydration solutions during illness — maintain perfusion and mucosal defense; follow pediatric formulas. Immune Deficiency Foundation

---

Immunity-booster / regenerative / stem-cell” drug concepts

1. Hematopoietic stem cell transplantation (HSCT)
   For CARD11 loss-of-function immunodeficiency, HSCT has been successful; for CARD11 GOF (BENTA), experience is limited and risks may outweigh benefits—decisions are individualized and rare. Immune Deficiency Foundation

2. Sirolimus (mTOR)
   Immunoregulator that can shrink lymphoid tissue and dampen overactive signaling; used case-by-case in BENTA. Dose must be individualized with level monitoring. PubMed Central

3. Abatacept (CTLA-4-Ig)
   Blocks costimulation to calm T-cell activation; occasionally used in immune dysregulation disorders to reduce autoimmunity; BENTA-specific data are sparse. U.S. Food and Drug Administration

4. Rituximab (anti-CD20)
   Temporarily removes B cells, reducing autoantibody production and EBV-infected B cells; re-dosing depends on relapse patterns and Ig recovery. FDA Access Data

5. IVIG (immunoglobulin replacement)
   Provides pooled antibodies to prevent infections and modulate autoimmunity; dosing is individualized by trough levels and clinical response. U.S. Food and Drug Administration

6. Targeted pathway inhibitors (clinical-trial context)
   Because CARD11 GOF activates CBM/NF-κB downstream of BTK, BTK inhibitors may have limited efficacy; research focuses on more proximal CBM/NF-κB modulators—consider clinical trials if available. Frontiers

---

Surgeries

1. Splenectomy (rare, last-line) — considered only for refractory hypersplenism/autoimmune cytopenias not controlled medically; increases lifelong infection risk (asplenia precautions needed). PubMed Central

2. Lymph node biopsy — diagnostic when malignancy or unusual infection is suspected. PubMed Central

3. Central line placement — for recurrent IV therapies; risks include infection/thrombosis—use only when necessary. Immune Deficiency Foundation

4. Tonsillectomy/adenoidectomy — occasionally for obstructive symptoms or recurrent otitis; benefit individualized. Immune Deficiency Foundation

5. Dental surgical drainage — source control for deep odontogenic infections in immunocompromised hosts. Immune Deficiency Foundation

---

Preventions

1. Up-to-date non-live vaccinations; live vaccines individualized. Immune Deficiency Foundation

2. Annual influenza vaccination for patient and household. Immune Deficiency Foundation

3. Hand hygiene; mask during local viral surges. Immune Deficiency Foundation

4. Safe food & water practices. Immune Deficiency Foundation

5. Dental hygiene and prompt dental care. Immune Deficiency Foundation

6. Early evaluation of fevers, rashes, breathing difficulty. PubMed Central

7. Avoid contact sports with splenomegaly. PubMed Central

8. Travel planning with standby meds. Immune Deficiency Foundation

9. Household vaccination “cocooning”. Immune Deficiency Foundation

10. Written emergency plan (fever pathway, contacts). Immune Deficiency Foundation

---

When to see a doctor (red flags)

Seek urgent care for fever, rapidly enlarging nodes or spleen, breathing difficulty, daytime sleepiness with high fevers, bruising/bleeding (possible cytopenias), severe sore throat (EBV), abdominal pain after minor trauma (splenic rupture risk), severe mouth ulcers, or prolonged diarrhea/vomiting causing dehydration. Regular follow-ups should review labs, EBV PCR, growth, school functioning, and vaccine/antimicrobial plans. PubMed Central+1

---

What to eat and what to avoid

1. Eat: balanced meals with adequate protein to rebuild after infections. Avoid: crash diets that risk malnutrition. Immune Deficiency Foundation

2. Eat: fruits/vegetables (washed, safely prepared). Avoid: unwashed produce. Immune Deficiency Foundation

3. Eat: pasteurized dairy. Avoid: unpasteurized milk/cheeses. Immune Deficiency Foundation

4. Eat: well-cooked meats/eggs. Avoid: undercooked animal products. Immune Deficiency Foundation

5. Hydrate: oral rehydration during illness. Avoid: energy drinks/high-sugar sodas. Immune Deficiency Foundation

6. Consider: vitamin D, zinc, omega-3 (with clinician). Avoid: mega-doses/supplement stacks without supervision. FDA Access Data

7. If on sirolimus: follow lipid-friendly diet; monitor triglycerides. FDA Access Data

8. If on TMP-SMX or antivirals: maintain hydration; watch for GI upset. FDA Access Data+1

9. Food safety when neutropenic: extra caution with raw foods; follow clinic list. U.S. Food and Drug Administration

10. Limit alcohol (adults) and avoid tobacco exposure to support immune and cardiometabolic health. Immune Deficiency Foundation

---

FAQs

1) Is BENTA cancer?
No. It’s polyclonal B-cell overgrowth from a genetic signaling problem, not a clonal cancer—but long-term monitoring is still important. PubMed

2) How is BENTA inherited?
Usually autosomal dominant: each child of an affected parent has a 50% chance to inherit the mutation. Wikipedia

3) What gene is involved?
CARD11. GOF variants hyperactivate the CBM (CARD11-BCL10-MALT1) complex and NF-κB. MedlinePlus

4) Why are T cells “anergic”?
Abnormal downstream signaling dampens T-cell activation, so responses are blunted despite normal counts. PubMed

5) Which infections are common?
Viral upper respiratory infections and EBV are common concerns; severity varies. PubMed Central

6) Is there a cure?
No established cure for CARD11 GOF; care is supportive/targeted. HSCT helps CARD11 loss-of-function, but its role in BENTA is uncertain. Immune Deficiency Foundation

7) Will my child need lifelong medicines?
Not always. Many children are managed with monitoring and intermittent treatments; therapy is individualized. PubMed Central

8) Is sirolimus standard for BENTA?
No single standard exists; case reports show benefit in selected patients, used by specialists with level monitoring. PubMed Central

9) Why might doctors use rituximab?
To deplete B cells temporarily when autoimmunity or EBV-driven issues arise. FDA Access Data

10) Does IVIG replace vaccines?
No. IVIG can help prevent infections but doesn’t replace individualized vaccine planning. U.S. Food and Drug Administration

11) Could BENTA look like ALPS or HLH?
Yes—overlap can occur (fever, splenomegaly, cytopenias), so genetic testing matters. PubMed

12) What labs are followed?
CBC with differential, lymphocyte subsets, immunoglobulins, EBV PCR, and organ size on exam/ultrasound as needed. PubMed Central

13) Any lifestyle restrictions?
If the spleen is enlarged, avoid contact sports; otherwise, encourage normal growth and activity with infection-prevention habits. PubMed Central

14) Could it get better with age?
Some children stabilize; others need intermittent therapy. Long-term course varies by mutation and clinical history. PubMed Central

15) Where can families learn more?
Primary Immune Deficiency resources and medical genetics pages give reliable background; bring questions to your immunology team. Immune Deficiency Foundation

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 22, 2025.